- Home
- FCAP vs ADAG Comparison
FCAP vs ADAG Comparison
Compare FCAP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | ADAG |
|---|---|---|
| Founded | 1891 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.1M | 260.3M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FCAP | ADAG |
|---|---|---|
| Price | $64.69 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 7.2K | ★ 270.7K |
| Earning Date | 04-24-2026 | 04-01-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 36.97 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $7,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.76 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $33.88 | $1.44 |
| 52 Week High | $71.00 | $4.85 |
Technical Indicators
Market Signals| Indicator | FCAP | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 62.38 |
| Support Level | $49.87 | $3.21 |
| Resistance Level | $68.14 | $4.66 |
| Average True Range (ATR) | 1.73 | 0.45 |
| MACD | -0.24 | 0.09 |
| Stochastic Oscillator | 41.19 | 75.46 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.